Pulmatrix (NASDAQ:PULM – Get Free Report) released its quarterly earnings results on Friday. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, Zacks reports. Pulmatrix had a negative return on equity of 45.97% and a negative net margin of 96.51%.
Pulmatrix Price Performance
PULM traded down $0.21 on Friday, hitting $7.40. The company had a trading volume of 1,606 shares, compared to its average volume of 131,939. Pulmatrix has a 52-week low of $1.56 and a 52-week high of $10.40. The stock has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $5.13. The firm has a market capitalization of $26.99 million, a P/E ratio of -2.80 and a beta of 1.66.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of Pulmatrix in a report on Sunday, January 5th. They issued a “hold” rating for the company.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- How to Effectively Use the MarketBeat Ratings Screener
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- What Investors Need to Know About Upcoming IPOs
- Micron Stock Will Retest All-Time Highs This Year
- What Are Growth Stocks and Investing in Them
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
